Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature

Kassem, Nancy; Ismail, Omar M; El-Omri, Halima; Yassin, Mohamed A

doi:10.12659/ajcr.903485

Cited by 5 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potentially severe ADRs with TKIs such as gastric polyps were also observed in the present study, which is similar to a case report by Qatar. 25 The high incidence of ADRs and the fact that TKI therapy is long-term warrant close pharmacovigilance of CML patients.…”

Section: Discussionmentioning

confidence: 99%

Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia

Tan

Chua

Chen

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Chronic myeloid leukaemia (CML) patients on long-term tyrosine kinase inhibitor (TKI) therapy are susceptible to drug-related problems (DRPs). This study aimed to evaluate the acceptability and outcomes of pharmacist-led interventions on DRPs encountered by CML patients. Methods This study included participants from the intervention arm of a randomised controlled trial which was conducted to evaluate the effects of pharmacist-led interventions on CML patients treated with TKIs. Participants were recruited and followed up in the haematology clinics of two hospitals in Malaysia from March 2017 to January 2019. A pharmacist identified DRPs and helped to resolve them. Patients were followed-up for six months, and their DRPs were assessed based on the Pharmaceutical Care Network Europe Classification for DRP v7.0. The identified DRPs, the pharmacist’s interventions, and the acceptance and outcomes of the interventions were recorded. A Poisson multivariable regression model was used to analyse factors associated with the number of identified DRPs per participant. Results A total of 198 DRPs were identified from 65 CML patients. The median number of DRPs per participants was 3 (interquartile range: 2, 4). Most participants (97%) had at least one DRP, which included adverse drug events (45.5%), treatment ineffectiveness (31.5%) and patients’ treatment concerns or dissatisfaction (23%). The 228 causes of DRPs identified comprised the following: lack of disease or treatment information, or outcome monitoring (47.8%), inappropriate drug use processes (23.2%), inappropriate patient behaviour (19.9%), suboptimal drug selection (6.1%), suboptimal dose selection (2.6%) and logistic issues in dispensing (0.4%). The number of concomitant medications was significantly associated with the number of DRPs (adjusted Odds Ratio: 1.100; 95% CI: 1.005, 1.205; p = 0.040). Overall, 233 interventions were made. These included providing patient education on disease states or TKI-related side effects (75.1%) and recommending appropriate instructions for taking medications (7.7%). Of the 233 interventions, 94.4% were accepted and 83.7% were implemented by the prescriber or patient. A total of 154 DRPs (77.3%) were resolved. Conclusions The pharmacist-led interventions among CML patients managed to identify various DRPs, were well accepted by both TKI prescribers and patients, and had a high success rate of resolving the DRPs.

show abstract

Section: Discussionmentioning

confidence: 99%

Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia

Tan

Chua

Chen

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Temsirolimus was used for the treatment of patients with renal cell carcinoma, multiple myeloma, and mantle cell lymphoma [75] . Nilotinib was considered a potential treatment for GC patients [32,79,80] . Two cases of GC were reported with nilotinib therapy in a post-marketing clinical use survey in Japan and one case was reported in a global phase III multicenter trial [80] .…”

Section: Discussionmentioning

confidence: 99%

Identification of Key Genes as Potential Drug Targets for Gastric Cancer

Hossain

Reza

Peng

et al. 2023

Tsinghua Sci. Technol.

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common cancers and ranks the third in cancer mortality all over the world. The goal of this study was to identify potential hub-genes, highlighting their functions, signaling pathways, and candidate drugs for the treatment of GC patients. We used publicly available next generation sequencing (NGS) data to identify differentially expressed (DE) genes. The top DE genes were mapped to STRING database to construct the protein-protein interaction (PPI) network and top hub genes were selected for further analysis. We found a total of 1555 DE genes with 870 upregulated and 685 downregulated genes in GC. We selected the top 400 (200 upregulated and 200 downregulated) genes to construct a PPI network and extracted the top 15 hub genes. The gene ontology (GO) term and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses of the 15 hub genes exposed some important functions and signaling pathways that were significantly associated with GC patients. The survival analysis of the hub genes disclosed that the lower expressions of the three hub genes CDH2, COL4A1, and COL5A2 were associated with better survival of GC patients. These three genes might be the candidate biomarkers for the diagnosis and treatment of GC. Then, we considered 3 key proteins (genomic biomarkers) (COL4A1, CDH2, and CO5A2) as the drug target proteins (receptors), performed their docking analysis with the 102 meta-drug agents, and found Everolimus, Docetaxel, Lanreotide, Venetoclax, Temsirolimus, and Nilotinib as the top ranked 6 candidate drugs with respect to our proposed target proteins for the treatment against GC patients. Therefore, the proposed drugs might play vital role for the treatment against GC patients.

show abstract

“…In fact, hyperplastic polyps are by-products of the damaged mucosa during its healing [18] . According to literature, the vast majority of fundic gland polyps occur in patients who are not infected with H. pylori [19,20] . In addition, long-term duodenal re ux can cause chronic in ammation, gastric pit cell hyperplasia, atypical hyperplasia, polyps, and other lesions [21,22] .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of gastric polyps in patients with upper gastrointestinal endoscopy

zheng¹,

wen²,

Dai³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:According to the study population, incidence of gastric polyps (GPs) varies from 0.33% to 6.7% in various studies. Most GPs consist of hyperplastic polyps (HPs), fundic gland polyps (FGPs), and adenomatous polyps (APs). Despite the high malignant APs potential, sporadic FGPs has no malignant potential. On the contrary, HPs has a lower risk of potential harm. It is not sufficient to perform biopsies to determine the presence of polyp types and displacements, therefore, some polyps may require extensive biopsy or complete resection. MethodsThis retrospective study included GPs patients or polyphenic lesions with polyps or malignant histology found in polyps or gastroscopy at the Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine from 2017 to 2019.ResultsIn a series of 10.000 upper gastrointestinal endoscopy, 384 patients (3.84%) were found to have GPs. Of these patients, 98 (25.5) were male and 286(74.5) were female. The average age of the patients was 62.8±10.4 (36-75) years. HPs, APs and FGPs frequencies were 88.5%, 5.2% and 2.1%, respectively. The polyp size of 274 (71.3%) patients was ≤ 1 cm. Polyp was identified in 262 (68.2%) patients. The most common polyps are the antrum and the corpus. Endoscopic mucosal resection was performed on 128 patients. Bleeding events have been observed and endoscopic treatment is required after ESP.Conclusion: In current study, GPs frequency was low (3.84%), and HP frequency may be high due to high frequency of Helicobacter pylori (HPy) infection in China. Due to the high frequency of HPy infection and the short-term use of proton pump use, FGP frequency may be low.

show abstract

Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature

Cited by 5 publications

References 26 publications

Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia

Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia

Identification of Key Genes as Potential Drug Targets for Gastric Cancer

Evaluation of gastric polyps in patients with upper gastrointestinal endoscopy

Contact Info

Product

Resources

About